Compare Mesoblast Limited (MESO) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Wolfspeed Inc — how do they compare? Mesoblast Limited trades at $14.31 (market cap $1.75B), while Wolfspeed Inc trades at $30.07 (market cap $1.64B). The key difference: Mesoblast Limited and Wolfspeed Inc are close in size by market cap, and Wolfspeed Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Wolfspeed Inc for 19 Days on average.
| MESO | WOLF | |
|---|---|---|
Market Cap | $1.75B | $1.64B |
Volume | 239,027 | 22,772,687 |
Sector | Health | Technology |
52-Week High | $20.96 | $73.68 |
52-Week Low | $13.19 | $14.80 |
Typical Hold Time | 14 Days | 19 Days |
Enterprise Value | $1.83B | $2.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Wolfspeed (WOLF) trades at $31.23, down 0.45% on the day, with a bullish technical signal driven by moving averages. The company reported a significant net loss of -$1.61B in 2025, with negative gross and net profit margins, though 2026 projections show potential for a small profit. Recent news highlights expansion of its 200mm silicon carbide portfolio, positioning it in the growing AI infrastructure sector.
The outlook is mixed; analyst consensus is a Buy with a $54.32 price target, suggesting substantial upside, but high execution risk remains due to persistent losses and ongoing legal investigations. Revenue growth and achieving profitability are critical for stock performance, with the transition to 800-volt AI data centers being a potential catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
